Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

Markowitz, 2018, Cabozantinib: a multitargeted oral tyrosine kinase inhibitor, Pharmacotherapy, 38, 357, 10.1002/phar.2076 Henley, 2020, Annual report to the nation on the status of cancer, part I: National cancer statistics, Cancer., 10.1002/cncr.32802 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med., 373, 1814, 10.1056/NEJMoa1510016 Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial, J. Clin. Oncol., 35, 591, 10.1200/JCO.2016.70.7398 Choueiri, 2021, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med., 384, 829, 10.1056/NEJMoa2026982 Escudier, 2018, Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial, J. Clin. Oncol., 36, 765, 10.1200/JCO.2017.74.7352 Umer, 2018, Skeletal metastasis in renal cell carcinoma: a review, Ann. Med. Surg. (Lond.), 27, 9, 10.1016/j.amsu.2018.01.002 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J. Clin. Oncol., 27, 5794, 10.1200/JCO.2008.21.4809 Heng, 2013, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol., 14, 141, 10.1016/S1470-2045(12)70559-4 Kroeger, 2013, Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria, Cancer, 119, 2999, 10.1002/cncr.28151 Dudani, 2020, Application of IMDC criteria across first-line (1 L) and second-line (2 L) therapies in metastatic renal-cell carcinoma (mRCC): new and updated benchmarks of clinical outcomes, J. Clin. Oncol., 38, 5063, 10.1200/JCO.2020.38.15_suppl.5063 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Liu, 2018, Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS ((R)) macros, F1000Res, 7, 1955, 10.12688/f1000research.16866.1 Cella, 2018, Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR Phase III randomized trial, J. Clin. Oncol., 36, 757, 10.1200/JCO.2017.75.2170 Mehta, 2016, Regression coefficient-based scoring system should be used to assign weights to the risk index, J. Clin. Epidemiol., 79, 22, 10.1016/j.jclinepi.2016.03.031 Sullivan, 2004, Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions, Stat. Med., 23, 1631, 10.1002/sim.1742 Uno, 2011, On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data, Stat. Med., 30, 1105, 10.1002/sim.4154 Martini D.J., Liu Y., Shabto J.M., Carthon B.C., Hitron E.E., Russler G.A., et al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 2019. Colotta, 2009, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, 30, 1073, 10.1093/carcin/bgp127 Lalani, 2018, Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma, J. Immunother. Cancer, 6, 5, 10.1186/s40425-018-0315-0 Bilen, 2019, The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy, Cancer, 125, 127, 10.1002/cncr.31778 Templeton, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, J. Natl. Cancer Inst., 106, dju124, 10.1093/jnci/dju124 Shabto, 2020, Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors, Cancer Med., 9, 2752, 10.1002/cam4.2932 Liu, 2014, Macrophage polarization in inflammatory diseases, Int. J. Biol. Sci., 10, 520, 10.7150/ijbs.8879 Mantovani, 2017, Tumour-associated macrophages as treatment targets in oncology, Nat. Rev. Clin. Oncol., 14, 399, 10.1038/nrclinonc.2016.217 Leek, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res., 56, 4625 De Palma, 2017, Microenvironmental regulation of tumour angiogenesis, Nat. Rev. Cancer, 17, 457, 10.1038/nrc.2017.51 Wang, 2017, Role of tumor microenvironment in tumorigenesis, J. Cancer, 8, 761, 10.7150/jca.17648 Haider, 2015, Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo, Bone, 81, 581, 10.1016/j.bone.2015.08.003 Dai, 2014, Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions, Clin. Cancer Res., 20, 617, 10.1158/1078-0432.CCR-13-0839 Wei, 2017, The pathology and molecular genetics of sarcomatoid renal cell carcinoma: a mini-review, J. Kidney Cancer VHL, 4, 19, 10.15586/jkcvhl.2017.70 Kondisetty, 2019, Retrospective review of experience with sarcomatoid renal cell carcinoma: multimodality treatment remains an unmet goal, Urol. Ann., 11, 385, 10.4103/UA.UA_106_18 Raychaudhuri, 2017, Immune check point inhibition in sarcomatoid renal cell carcinoma: a new treatment paradigm, Clin. Genitourin. Cancer, 15, e897, 10.1016/j.clgc.2017.05.018 Mian, 2002, Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma, J. Urol., 167, 65, 10.1016/S0022-5347(05)65384-0 Keskin, 2017, Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras, J. Urol., 198, 530, 10.1016/j.juro.2017.04.067 Hanif, 2019, Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors, Oncoimmunology, 8, 10.1080/2162402X.2019.1606639 Koshkin, 2018, Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immuno.Therapy Cancer, 6, 9, 10.1186/s40425-018-0319-9 Motzer, 1999, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, J. Clin. Oncol., 17, 2530, 10.1200/JCO.1999.17.8.2530 Hsu, 2013, Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system, Hepatology, 57, 112, 10.1002/hep.25950 Dolan R.D., Daly L., Sim W.M.J., Fallon M., Ryan A., McMillan D.C., et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin. Nutr. Simmons, 2019, How long have I got?”—A prospective cohort study comparing validated prognostic factors for use in patients with advanced cancer, Oncologist, 24, e960, 10.1634/theoncologist.2018-0474